Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ScinoPharm Taiwan Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

23 Jul 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - ScinoPharm Taiwan Ltd (1789-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

29 Jul 2016 Thomson Reuters Stock Report 11 $25.00

Scinopharm Taiwan Limited (1789) - Financial Analysis Review

Scinopharm Taiwan Limited (1789) - Financial Analysis Review Summary Scinopharm Taiwan Limited (ScinoPharm) is a pharmaceutic...

15 Jul 2016 GlobalData 42 $300.00

Wright Investors Service Comprehensive Report for Scinopharm Taiwan Limited

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

28 Jun 2016 Wright Reports 60 $75.00

Scinopharm Taiwan Limited (1789) - Financial Analysis Review

Scinopharm Taiwan Limited (1789) - Financial Analysis Review Summary ScinoPharm Taiwan, Ltd. (ScinoPharm) is a pharmaceutical...

16 Jun 2016 GlobalData 43 $300.00

神隆(1789.TT)營運轉型步伐不歇,惟評價不低

營運轉型步伐不歇,惟評價仍不低,維持中立:神隆近年除鞏固其在高活性原料藥端之優勢地位外,在營運上也積極將觸角透過策略聯盟方式向下延伸至下游製劑開發,以其中長期能再提高公司整體之利潤,惟此部分成效非一蹴可及、需待時間觀察外,目前評價上也不低,故維持中立建議。

15 Jun 2016 SinoPac Sec Inv Service 4 $23.00

Is Scinopharm Taiwan Limited Stock Still Attractive?

25 May 2016 Sadif Analytics Prime 12 $25.00

ScinoPharm Taiwan (1789 TT): Launch of Generic Drugs Behind Schedule

The plant in Changshou serves as ScinoPharm’s major growth engine. However, due to clients’ generic drug development behind s...

15 May 2016 MasterLink Securities Corporation 6 $58.00

神隆 (1789):2016年學名藥上市進度與毛利率不如預期

神隆2016年成長動能主要來自常熟廠,然學名藥進度不如預期,我們將神隆2016營收從45.5億元下修至43.8億元,YOY +11%;毛利率部分,主力產品Docetaxel有降價壓力,我們亦將2016毛利率從45.4%下修至44.3%,2016年EP...

11 May 2016 MasterLink Securities Corporation 5 $35.00

神隆(1789.TT) 評價合理,維持中立

投資建議維持中立:投資建議部分,雖公司積極往下游製劑發展有助提升產業競爭力,唯此部分預見實質獲利貢獻仍需時間等待,加以目前本益比仍偏高,故維持中立建議

11 May 2016 SinoPac Sec Inv Service 5 $35.00